AM Rx vs Midi Health
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
AM Rx
Best for patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully)Starting at $25/mo
Midi Health
Best for women in menopause / perimenopause with commercial insurance who want GLP-1 prescribing as part of a broader hormone + metabolic care plan, not as a standalone weight-loss productStarting at $128/mo
Side-by-Side Comparison
| Feature | AM Rx | Midi Health |
|---|---|---|
| Overall Score | 5.9/10 | ✓7.0/10 |
| Starting Price | ✓$25/mo | $128/mo |
| Editorial Rating | 3 ★ /5 | ✓3.5 ★ /5 |
| Features | ✓6 features | 4 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | 2 warnings | ✓None |
Pros & Cons
AM Rx
Pros
- ✓Insurance coordination for brand-name GLP-1s — as low as $25/mo
- ✓All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- ✓HSA and FSA accepted
- ✓Video visits available (not just async) with providers averaging 10+ years experience
- ✓Compounded semaglutide from $151/mo quarterly
Cons
- ✗Active FTC/DOJ lawsuit for deceptive billing and subscription practices (ROSCA violations)
- ✗Two FDA warning letters (Sept 2025, Feb 2026) for misbranding compounded GLP-1 products
- ✗Novo Nordisk false advertising lawsuit (Aug 2025)
- ✗Parent entity Zealthy has BBB D- rating with 2,370+ complaints
- ✗Trustpilot 2.0/5 — 85% one-star reviews citing billing disputes and unreachable support
- ✗No visible LegitScript certification or PCAB accreditation
- ✗No named pharmacy partners — compounding source not disclosed
- ✗No FDA compounding disclaimer on the website
- ✗State availability not publicly disclosed
- ✗Founder Kyle Robertson previously ran Cerebral, which settled FTC charges for similar practices
- ✗Same corporate entity (FitRX LLC) as Zealthy and FitRx — shares regulatory history
Midi Health
Pros
- ✓Nationwide availability in all 50 states (verified on the public homepage)
- ✓Accepts commercial insurance — differentiator vs most cash-pay-only GLP-1 telehealth
- ✓Menopause + metabolic health specialty framing — useful for women in the demographic where GLP-1 efficacy and weight regulation overlap most
- ✓Compounded semaglutide pricing starts at $127.90/mo for uninsured patients per the public pricing/insurance page
Cons
- ✗Does NOT accept Medicare, Medicaid, or Medi-Cal — eliminates roughly 40% of the insured US adult population
- ✗GLP-1 prescribing is clinician-discretionary inside a broader menopause care plan, NOT a guaranteed offering at intake — readers signing up purely for GLP-1 access may not get it
- ✗Menopause-focused — not the right fit for men or younger women whose primary need is weight loss
Our Verdict
Midi Health edges out AM Rx with a higher overall score of 7.0/10 and is particularly strong for women in menopause / perimenopause with commercial insurance who want GLP-1 prescribing as part of a broader hormone + metabolic care plan, not as a standalone weight-loss product. AM Rx remains a solid alternative, especially if you're looking for patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully).
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.